PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc. a leading provider of the end-to-end platform for digitally enabled and data-driven clinical trials, today announced the organization’s Cortex application and infrastructure has earned Certified status for information security by HITRUST.
HITRUST CSF Certified status demonstrates that the organization’s Cortex application and infrastructure has met key regulatory requirements and industry-defined requirements and is appropriately managing risk. This achievement places Medable in an elite group of organizations worldwide that have earned this certification. By including federal and state regulations, standards and frameworks, and incorporating a risk-based approach, the HITRUST CSF helps organizations address these challenges through a comprehensive and flexible framework of prescriptive and scalable security controls.
“Organizations, like ours, are under great pressure to meet complex compliance requirements that include technical and process elements such as HIPAA, ISO and COBIT,” said Perry Robinson, Chief Compliance Officer at Medable. “The HITRUST CSF is the gold-standard that needs to be met, and Medable is pleased to be able to demonstrate its commitment by achieving HITRUST CSF Certification.”
“The HITRUST CSF has become the information protection framework for the health care industry, and the CSF Assurance program is bringing a new level of effectiveness and efficiency to third-party assurance,” said Ken Vander Wal, Chief Compliance Officer, HITRUST. “The HITRUST CSF Certification is now the benchmark that organizations required to safeguard PHI are measured against with regards to information protection.”
Medable is a privately held, venture-backed company headquartered in Palo Alto, California. Medable is on a mission to get effective therapies to patients faster by dramatically reducing the time from therapeutic development to market realization with digital data capture and real-time analytics that remove the complexities clinical research to dramatically reduce trial timelines. Medable is pioneering a new category of life science technologies that replace the stagnant and siloed data of traditional ePRO, eCOA, EDC, and eSource with an intelligent and unified end-to-end (E2E) platform for clinical trial execution. Our platform allows patients, healthcare providers, clinical research organizations and pharmaceutical sponsors to work together as a connected and empowered team in clinical trials.
For more information, visit www.medable.com and follow Medable on Twitter: @Medableinc